The influence of steroid type on outcomes in patients with acute respiratory distress syndrome

被引:1
作者
Yoshihro, Shodai [1 ]
Taito, Shunsuke [2 ]
Yatabe, Tomoaki [3 ]
机构
[1] Hiroshima Univ Hosp, Dept Pharmaceut Serv, 1-2-3,Kasumi,Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ Hosp, Dept Clin Practice & Support, Div Rehabil, 1-2-3, Kasumi,Minami Ku, Hiroshima 7348551, Japan
[3] Nishichita Gen Hosp, Emergency Dept, 3-1,Nakanoike, Tokai, Aichi 4778522, Japan
关键词
Acute respiratory distress syndrome; Dosing; Corticosteroid; Pharmacology; METHYLPREDNISOLONE; DEXAMETHASONE; ARDS;
D O I
10.1186/s40560-023-00681-4
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background Recent systematic reviews and meta-analyses have suggested that low-dose steroids are effective in the treatment of acute respiratory distress syndrome (ARDS). Recent guidelines recommend the use of low-dose steroids instead of high-dose steroids. These systematic reviews were conducted based on the concept that the effect of steroids is constant regardless of their type. We discuss whether the type of steroid used influences the outcomes in patients with ARDS.Main body From a pharmacological standpoint, methylprednisolone has little activity as a mineralocorticoid and may cause pulmonary hypertension. The results of the rank probability of our previous network meta-analysis revealed that low-dose methylprednisolone might be an optimal treatment compared to using other types of steroids or no steroids in terms of ventilator-free days. Similarly, an analysis of individual data from four randomized controlled trials suggested that low-dose methylprednisolone was associated with decreased mortality in patients with ARDS. Dexamethasone has attracted the attention of clinicians as a novel adjunct therapy for ARDS.Conclusion Recent evidence has shown that low-dose methylprednisolone may be an effective treatment option for ARDS. The timing of initiation and duration of low-dose methylprednisolone therapy should be verified in future studies.
引用
收藏
页数:5
相关论文
共 24 条
  • [1] Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017
    Annane, Djillali
    Pastores, Stephen M.
    Rochwerg, Bram
    Arlt, Wiebke
    Balk, Robert A.
    Beishuizen, Albertus
    Briegel, Josef
    Carcillo, Joseph
    Christ-Crain, Mirjam
    Cooper, Mark S.
    Marik, Paul E.
    Meduri, Gianfranco Umberto
    Olsen, Keith M.
    Rodgers, Sophia
    Russell, James A.
    Van den Berghe, Greet
    [J]. INTENSIVE CARE MEDICINE, 2017, 43 (12) : 1751 - 1763
  • [2] Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat
    Ayyar, Vivaswath S.
    Song, Dawei
    DuBois, Debra C.
    Almon, Richard R.
    Jusko, William J.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 370 (02) : 318 - 326
  • [3] Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis
    Chaudhuri, Dipayan
    Sasaki, Kiyoka
    Karkar, Aram
    Sharif, Sameer
    Lewis, Kimberly
    Mammen, Manoj J.
    Alexander, Paul
    Ye, Zhikang
    Lozano, Luis Enrique Colunga
    Munch, Marie Warrer
    Perner, Anders
    Du, Bin
    Mbuagbaw, Lawrence
    Alhazzani, Waleed
    Pastores, Stephen M.
    Marshall, John
    Lamontagne, Francois
    Annane, Djillali
    Meduri, Gianfranco Umberto
    Rochwerg, Bram
    [J]. INTENSIVE CARE MEDICINE, 2021, 47 (05) : 521 - 537
  • [4] Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
    Edalatifard, Maryam
    Akhtari, Maryam
    Salehi, Mohammadreza
    Naderi, Zohre
    Jamshidi, Ahmadreza
    Mostafaei, Shayan
    Najafizadeh, Seyed Reza
    Farhadi, Elham
    Jalili, Nooshin
    Esfahani, Masoud
    Rahimi, Besharat
    Kazemzadeh, Hossein
    Aliabadi, Maedeh Mahmoodi
    Ghazanfari, Tooba
    Sattarian, Mohammadreza
    Louyeh, Hourvash Ebrahimi
    Raeeskarami, Seyed Reza
    Jamalimoghadamsiahkali, Saeidreza
    Khajavirad, Nasim
    Mahmoudi, Mahdi
    Rostamian, Abdolrahman
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)
  • [5] The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition
    Flammer, Jamie R.
    Dobrovolna, Jana
    Kennedy, Megan A.
    Chinenov, Yurii
    Glass, Christopher K.
    Ivashkiv, Lionel B.
    Rogatsky, Inez
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (19) : 4564 - 4574
  • [6] Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
    Hirano, Yohei
    Madokoro, Shunsuke
    Kondo, Yutaka
    Okamoto, Ken
    Tanaka, Hiroshi
    [J]. JOURNAL OF INTENSIVE CARE, 2020, 8 (01)
  • [7] Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung
    Jalkanen, Juho
    Pettila, Ville
    Huttunen, Teppo
    Hollmen, Maija
    Jalkanen, Sirpa
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (10) : 1937 - 1940
  • [8] Effects of cytokines and endotoxin on the intracellular growth of bacteria
    Kanangat, S
    Meduri, GU
    Tolley, EA
    Patterson, DR
    Meduri, CU
    Pak, C
    Griffin, JP
    Bronze, MS
    Schaberg, DR
    [J]. INFECTION AND IMMUNITY, 1999, 67 (06) : 2834 - 2840
  • [9] Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells
    Kowalski, Jessica
    Deng, Lisa
    Suennen, Chiara
    Koca, Duygu
    Meral, David
    Bode, Christoph
    Hein, Lutz
    Lother, Achim
    [J]. HYPERTENSION, 2021, 78 (02) : 456 - 465
  • [10] Corticosteroids in H1N1, non-viral, and COVID-19 ARDS
    Kwon, Kyoung-Eun
    Jung, Sun-Young
    Baek, Moon Seong
    Kim, Won-Young
    [J]. INTENSIVE CARE MEDICINE, 2022, 48 (12) : 1809 - 1811